$1.01
+0.13
(+15.15%)▲
In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 133.4%
8.91%
Downside
Day's Volatility :11.54%
Upside
2.88%
21.78%
Downside
52 Weeks Volatility :90.97%
Upside
88.46%
Period | PRAXIS PRECISION MEDICINES I | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -69.96% | 0.7% | -7.0% |
6 Months | -59.95% | -7.9% | -6.5% |
1 Year | -89.37% | -2.0% | -6.8% |
3 Years | -96.84% | 25.4% | 24.7% |
Market Capitalization | 53.0M |
Book Value | $1.11 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.33 |
Wall Street Target Price | 9.13 |
Profit Margin | 0.0% |
Operating Margin TTM | -26973.35% |
Return On Assets TTM | -68.15% |
Return On Equity TTM | -143.07% |
Revenue TTM | 683.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -183.8M |
Diluted Eps TTM | -3.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.67 |
EPS Estimate Next Year | -2.36 |
EPS Estimate Current Quarter | -0.79 |
EPS Estimate Next Quarter | -0.75 |
What analysts predicted
Upside of 803.96%
Sell
Neutral
Buy
PRAXIS PRECISION MEDICINES I is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() PRAXIS PRECISION MEDICINES I | -14.84% | -59.95% | -89.37% | -96.84% | -96.84% |
![]() Moderna, Inc. | -2.19% | -29.52% | -8.32% | 114.67% | 590.97% |
![]() Regeneron Pharmaceuticals, Inc. | -8.43% | -4.6% | 15.93% | 18.38% | 134.28% |
![]() Seagen, Inc. | -2.63% | 59.03% | 43.99% | 21.05% | 216.49% |
![]() Vertex Pharmaceuticals Incorporated | -6.48% | 0.7% | 19.84% | 13.84% | 116.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() PRAXIS PRECISION MEDICINES I | NA | NA | NA | -2.67 | -1.43 | -0.68 | 0.0 | 1.11 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() PRAXIS PRECISION MEDICINES I | Buy | $53.0M | -96.84% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 590.97% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 134.28% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.7B | 216.49% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 116.25% | 26.18 | 35.4% |
Velan Capital Investment Management LP
Avidity Partners Management LP
Eventide Asset Management, LLC
BlackRock Inc
Verition Fund Managegment, LLC
Kingdon Capital Management LLC
PRAXIS PRECISION MEDICINES I’s price-to-earnings ratio stands at None
Read MorePraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.
Organization | PRAXIS PRECISION MEDICINES I |
Employees | 109 |
CEO | Mr. Marcio Souza M.B.A. |
Industry | Health Technology |
PowerShares SP MidCap Low Volatility ETF
$51.27
+2.97%
SPDR NYSE Technology ETF
$132.98
+0.91%
ProShares UltraPro Dow30 ETF
$57.18
+6.4%
Teucrim Soybean Fund
$24.73
+1.24%
CRESCENT CAPITAL BDC INC
$13.65
+0.15%
Fusion Pharmaceuticals Inc
$4.90
-2.39%
AMC Networks Inc.
$11.64
+2.02%
EVGO INC CL A
$4.03
+0.5%
CONNECT BIOPHARMA HOLDINGS L
$1.22
+9.91%